AGÕæÈ˹ٷ½

A Form 4 filed on 07/08/2025 discloses that Stephen Neeleman, founder, Vice-Chairman and director of HealthEquity, Inc. (HQY), disposed of 1,049 common shares on 07/03/2025 at an average price of $100.8721 under transaction code "F", indicating shares were withheld to satisfy taxes or exercise costs rather than an open-market sale.

After the withholding, Neeleman continues to hold 112,593 shares directly and 756,235 shares indirectly through a trust and family LLC, leaving his total ownership at approximately 868,828 shares. The disposition equals roughly 0.12 % of his aggregate holdings, suggesting no material change in insider alignment.

Table II shows three fully vested option grants with strike prices of $41.28, $61.72 and $73.61, covering a combined 49,462 shares that remain outstanding and immediately exercisable.

No other share sales, purchases or derivative exercises were reported. Given the small size and tax-related nature of the transaction, the filing is operationally and financially immaterial for HQY shareholders.

Torrid Holdings Inc. (CURV) � Form 4 filing dated 7 July 2025 details Senior Vice President & Chief Accounting Officer Chinwe Abaelu’s latest equity activity.

• Transaction: 746 common shares were withheld (Code F) on 06 Jul 2025 to cover payroll taxes arising from the vesting of previously granted restricted stock.
• Price: $2.90 per share, implying a tax-related value of roughly $2,163.
• Post-transaction ownership: 136,687 common shares held directly.
• Additional holdings disclosure: figure includes 1,000 shares purchased under the 2021 Employee Stock Purchase Plan for the 1 Jan â€� 30 Jun 2025 period at 85 % of the 30 Jun closing price.
• Role: Officer status confirmed; filing made individually.

This event represents a non-discretionary, tax-related share disposition. The officer’s net ownership remains substantial, and the concurrent ESPP purchase indicates ongoing equity participation rather than a market-driven sale. Overall investment significance is limited.

Upstart Holdings, Inc. (UPST) â€� Form 144 insider notice

Insider Natalia Mirgorodskaya has filed to sell up to 6,533 common shares through Charles Schwab on or about 07/02/2025. At the reference price used in the filing, the transaction is valued at roughly $457,674. The shares were obtained the same day via an employee stock-option cashless exercise. Mirgorodskaya also disclosed two prior sales in the last three months�764 shares for $35,874 on 05/20/2025 and 1,340 shares for $59,215 on 05/23/2025.

With 95,144,858 shares outstanding, the proposed sale represents approximately 0.007 % of total shares, indicating a limited potential impact on the float. The filer certified that no undisclosed adverse information is known, in accordance with Rule 144 requirements.

Venus Concept Inc. (NASDAQ: VERO) has completed a series of related financing amendments designed to ease near-term liquidity pressure and realign its capital structure.

On 30 June 2025 the Company executed an Exchange Agreement with its senior lender Madryn Health Partners. Two existing secured subordinated convertible notes with aggregate principal of $17.0 million were exchanged for (i) new promissory notes totalling $11.1 million and (ii) 325,651 shares of newly issued Series Y Convertible Preferred Stock priced at $19.96 per share. Each preferred share converts into 9.0909 common shares, implying potential issuance of roughly 3.0 million additional common shares once conversion limits are lifted.

The transaction immediately reduces debt principal by about $5.9 million, shifts a portion of lender exposure into equity and carries no registration requirement under Section 3(a)(9). A Third Amended & Restated Registration Rights Agreement obligates the Company to file a shelf registration for the conversion shares within 60 days after all preferred shares convert.

Concurrently, the Company and Madryn executed several consent and amendment agreements: (1) waiver of minimum liquidity covenants on both the Main Street Priority Loan and the new notes through 31 July 2025, (2) permission to apply the 8 July 2025 interest payment to principal, and (3) a sixteenth amendment to the Bridge Loan extending maturity by one month to 31 July 2025.

To support the larger preferred issuance, Venus filed a Certificate of Amendment increasing authorized Series Y shares from 1.2 million to 1.5 million. A shareholder vote will be sought to remove Nasdaq-related conversion limits.

Overall, the package provides short-term covenant relief and modest debt reduction but adds potential equity dilution and highlights ongoing liquidity constraints, with several key maturities now deferred only to late July 2025.